Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trialDaniel S. Reich, Sibyl Wray, Robert J. Fox et al.|The Lancet Neurology|2021Cited by 192
Neuromyelitis optica spectrum disordersMaría Sepúlveda, Inmaculada Puertas, Thaís Armangué et al.|Neurology Neuroimmunology & Neuroinflammation|2016Cited by 153